Top Story
- Medical Affairs
Lenz Therapeutics made its Nasdaq debut through a reverse merger, a strategic choice that CEO Eef Schimmelpennink discussed with Endpoints News, emphasizing the financial benefits over a traditional IPO. The biotech company is on the verge of announcing Phase 3 data for its two presbyopia eye [...]
Latest Stories
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
The live session will focus on the latest salary and bonus trends for professionals in the field, including a comprehensive overview [...]
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
Vertex Pharmaceuticals Incorporated VRTX date announcement
Vertex Pharmaceuticals Incorporated, makers of Suzetrigine (VX-548), will be announcing their top-line results for the drug's recent NDA Filing trial on August 31, 2024. Our calculations show a 70.7% chance that the drug makes [...]
Read MoreImmutep Limited IMMP results announcement
Immutep Limited released new information about their Phase 1 trial for IMP761. Our analysts provided the following summary:
"Trial planned for mid-2024."
This is one of three upcoming announcements for the company.
The market was [...]
Read MoreBenitec Biopharma BNTC date announcement
On August 31, 2024, Benitec Biopharma will announce top-line results for their recent Phase 1 trial for BB-301. Our calculations show a 65.1% chance that the drug makes it to the next stage.
The announcement [...]
Read MoreNRX Pharmaceuticals OCUL date announcement
Ocular Therapeutix has an announcement scheduled for June 30, 2024 regarding their recent Phase 1 trial of AXPAXLI (OTX-TKI) - (HELIOS). Our predictive system gives the drug a 71.9% chance of making it to the [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest